ACM
KRYS icon

Aquatic Capital Management’s Krystal Biotech KRYS Stock Holding History

Aquatic Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,257
Closed -$2.13M – 1511
2026
Q1 		$2.13M Buy
+8,257
New +$2.2M 0.06% 358
2025
Q1 		– Sell
-6,901
Closed -$1.08M – 1460
2024
Q4 		$1.08M Buy
+6,901
New +$1.22M 0.03% 524
2024
Q2 		– Sell
-1,000
Closed -$178K – 1429
2024
Q1 		$178K Buy
+1,000
New +$139K 0.01% 789
2023
Q4 		– Sell
-1,400
Closed -$162K – 1490
2023
Q3 		$162K Buy
1,400
+1,300
+1,300% +$159K 0.01% 725
2023
Q2 		$12K Sell
100
-800
-89% -$81.7K ﹤0.01% 1181
2023
Q1 		$72K Buy
+900
New +$70.7K ﹤0.01% 815
2022
Q2 		– Sell
-100
Closed -$7K – 1404
2022
Q1 		$7K Sell
100
-1,200
-92% -$74.9K 0.01% 758
2021
Q4 		$91K Buy
+1,300
New +$75.7K 0.18% 151

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Aquatic Capital Management's KRYS Position: Q2 2026 in Review

Aquatic Capital Management sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 8,257 shares — an estimated $2.13M sold.

Aquatic Capital Management first reported a position in KRYS in Q4 2021 and held it in 8 quarters. The position peaked at $2.13M in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Aquatic Capital Management reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 8,257 Krystal Biotech shares in Q2 2026, an estimated $2.13M.
  • Aquatic Capital Management first reported a position in Krystal Biotech in Q4 2021 and held it in 8 quarters.
  • Aquatic Capital Management's Krystal Biotech position peaked at $2.13M in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.